Effects of combination treatment of bortezomib and dexamethasone in SCCHN cell lines depend on tumor cell specificity

Oncology Reports

Volumn 20, Issue 5, 2008, Pages 1207-1211

  Wagenblast, Jens ^a   Baghi, Mehran ^a   Arnoldner, Christoph ^a   Bisdas, Sotirios ^a   Gstöttner, Wolfgang ^a   May, Angelika ^a   Knecht, Rainald ^a   Hambek, Markus ^a  

^a GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

Author keywords

Bortezomib; Dexamethasone; Squamous cell carcinoma of the head and neck cell lines

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL SPECIFICITY; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ASSAY; GROWTH INHIBITION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; INHIBITION KINETICS; MULTIPLE MYELOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA; TUMOR CELL; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; HEAD AND NECK TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; DEXAMETHASONE; DRUG SCREENING ASSAYS, ANTITUMOR; HEAD AND NECK NEOPLASMS; HUMANS; PYRAZINES;

EID: 58149330691     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000131     Document Type: Article

References (14)

1. Kotz T, Costello R, Li Y and Posner MR: Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck. Head Neck 26: 365-372, 2004.
2. Gassler N, Zhang C, Wenger T, Schnabel PA, Dienemann H, Debatin KM, Mattern J and Herr I: Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo. Br J Cancer 92: 1084-1088, 2005.
3. Reuter CW, Morgan MA and Eckardt A: Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 96: 408-416, 2007.
4. Wagenblast J, Hambek M, Baghi M, Gstöttner W, Strebhardt K, Ackermann H and Knecht R: Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 134: 323-330, 2008.
5. Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL and Anderson KC: Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 91: 929-934, 2006.
6. Kirkbride P, Bezjak A, Pater J, Zee B, Palmer MJ, Wong R, Cross P, Gulavita S, Blood P, Sun A, Dundas G, Ganguly PK, Lim J, Chowdhury AD, Kumar SE and Dar AR: Dexamethasone for the prophylaxis of radiation-induced emesis: A National Cancer Institute of Canada Clinical Trials Group phase III study. J Clin Oncol 18: 1960-1966, 2000.
7. Brady ME, Sartiano GP, Rosenblum SL, Zaglama NE and Bauguess CT: The pharmacokinetics of single high doses of dexamethasone in cancer patients. Eur J Clin Pharmacol 32: 593-596, 1987.
8. Planey SL and Litwack G: Glucocorticoid-induced apoptosis in lymphocytes. Biochem Biophys Res Commun 279: 307-312, 2000.
9. Herr I and Pfitzenmaier J: Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol 7: 425-430, 2006.
10. Rutz HP: Effects of corticosteroid use on treatment of solid tumours. Lancet 360: 1969-1970, 2002.
11. Sherlock P and Hartmann WH: Adrenal steroids and the pattern of metastases of breast cancer. JAMA 181: 313-317, 1962.
12. Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH and Karagas MR: Skin cancers and non-Hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 96: 709-711, 2004.
13. Zhang C, Beckermann B, Kallifatidis G, Liu Z, Rittgen W, Edler L, Buchler P, Debatin KM, Buchler MW, Friess H and Herr I: Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma. Int J Oncol 29: 1295-1301, 2006.
14. Fidler IJ, Gersten DM and Kripke ML: Influence of immune status on the metastasis of three murine fibrosarcomas of different immunogenicities. Cancer Res 39: 3816-3821, 1979.